Breast Cancer Management Guidelines

Introduction to Breast Cancer Treatment

The National Comprehensive Cancer Network (NCCN) provides comprehensive, evidence-based recommendations for breast cancer management across all stages, with treatment decisions primarily driven by tumor biology, anatomic stage, and patient factors, delivered through a multidisciplinary team approach 1
The NCCN strongly recommends patient participation in clinical trials at all stages of breast cancer as the preferred treatment option 2, 3, 1

For clinical stage 0, I, or II disease, the essential baseline workup includes history and physical examination, bilateral diagnostic mammography, breast ultrasound as indicated, pathology review with ER/PR status, HER2 determination, complete blood count, platelet count, liver function tests, and genetic counseling if high-risk 4
Routine staging studies (bone scan, CT, abdominal imaging) should be avoided in stage I or II disease unless signs or symptoms suggest metastatic disease 4
For clinical T3N1M0 disease, additional staging studies including bone scan, abdominal imaging, and chest imaging are required due to higher risk of occult metastases 4

Adjuvant endocrine therapy is the cornerstone to reduce recurrence risk in hormone receptor-positive, HER2-negative breast cancer 1
For premenopausal women at diagnosis, tamoxifen for 5 years ± ovarian suppression/ablation (Category 1) or aromatase inhibitor for 5 years + ovarian suppression/ablation (Category 1) are recommended 3, 5
For postmenopausal women at diagnosis, aromatase inhibitor for 5 years (Category 1) or tamoxifen for 2-3 years followed by aromatase inhibitor to complete 5 years (Category 1) are recommended 3, 1
Chemotherapy is added selectively based on recurrence risk assessment in hormone receptor-positive, HER2-negative breast cancer 1
All patients with HER2-positive disease should receive HER2-directed therapy combined with chemotherapy 1

Preoperative systemic therapy facilitates breast conservation, renders inoperable tumors operable, and provides critical prognostic information based on treatment response 5, 1
Ideal candidates for preoperative systemic therapy include patients with inoperable breast cancer, HER2-positive disease ≥cT2 or ≥cN1, triple-negative breast cancer ≥cT2 or ≥cN1, and patients desiring breast conservation with large tumors 5, 1

Options for early-stage disease include breast-conserving surgery with radiation therapy or mastectomy with or without reconstruction 1
Whole breast radiation therapy is recommended after breast-conserving surgery 1
Post-mastectomy radiation is indicated for high-risk features 1
Primary approach for metastatic disease with intact primary is systemic therapy, not surgery 3, 1

Primary goals for recurrent/Stage IV disease are palliating symptoms, prolonging survival, and maintaining or improving quality of life 3, 1
Systemic therapy selection is based on hormone receptor status, HER2 status, tumor burden, and patient preference 3
For HER2-positive metastatic disease, continue HER2-targeted therapy even after progression 6
Evaluate response every 2-4 months for endocrine therapy or after 2-4 cycles for chemotherapy in metastatic setting 1, 6

Integrate expert palliative care early in the treatment course from time of metastatic diagnosis 3, 6
Avoid invasive dental procedures during bone-modifying agent treatment due to osteonecrosis risk 6